Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 36 (6) , 391-398
- https://doi.org/10.2165/00003088-199936060-00001
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.Journal of Clinical Oncology, 1998
- Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trialCancer, 1995
- No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusionBritish Journal of Cancer, 1992
- Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.1991
- Relative Importance of Dose, Body Surface Area, Sex, and Age for 5-Fluorouracil ClearanceOncology, 1991
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.1988
- Circadian rhythm of rat liver dihydropyrimidine dehydrogenaseBiochemical Pharmacology, 1988
- Dose Versus pharmacokinetics for predicting tolerance to 5‐day continuous infusion of 5‐FUInternational Journal of Cancer, 1988
- Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastasesBritish Journal of Cancer, 1988